S.1.1. General methods and analytical techniques
Commercial reagents were used as purchased. When required, solvents were dried following standard procedures. 1 1 H and 13 C-NMR spectra were recorded on a 400 MHz NMR spectrometer Bruker Avance III 400. 1 H-NMR-chemical shifts are referred to the residual signal of CDCl3 (δH 7.27) and 13 C-NMR-chemical shifts to the CDCl3 signal (δC 77.0), or using TMS as internal standard. Thin-layer chromatography was carried out on silica gel 60 F254 plates (AL TLC 20x20). Column chromatography was performed on Silica Gel 60 (0.04 -0.063 mm). IR spectra were recorded on a Tensor 27 FT/IR spectrometer in the 600-3800 cm -1 range. Melting points (°C) were obtained on a SMP3 Melting Point Apparattus and are uncorrected.
S.1.2. Preparation of intermediate building blocks
The synthetic approach followed to the preparation of intermediate blocks for the synthesis of final target compounds is illustrated in Schemes S3-S5. Synthetic procedures for each compound prepared are also provided in this section.
S.1.2.1. Preparation of 3-chloro-1,2-benzisothiazole-1,1-dioxide Scheme S3
The experimental procedure used has been reported previously. 2 
2-methyl-2H-tetrazole-5-amine, LC126II 4
The filtrate from 1-methyl-1H-tetrazole-5-amine LC126I synthesis was evaporated under reduced pressure to afford a solid residue. Water (50 mL) was added, and the mixture was then extracted with diethyl ether (3 x 50 mL). The organic extract was dried over anhydrous sodium sulfate, filtered, and the filtrate evaporated to afford colourless crystals. A solution of di-tert-butyl dicarbonate (2.50 x 10 -2 mol) in 1,4-dioxane (100 mL), under stirring, was added by cannula, over 3 hours, to a stirring solution of 1,4-diaminobutane (1.40
x 10 -1 mol) in 1,4-dioxane (100 mL). The final reaction mixture was stirred at room temperature for 20 h and then concentrated under reduced pressure. Water was added to precipitate the formed conjugate. The aqueous residue was extracted with DCM (2 x 30 mL). 
S.1.3. Synthetic route to trioxolanes
The synthetic approach followed to trioxolanes is illustrated in Scheme S6. Synthetic procedures for the preparation of each compound are also provided in this section (as described in literature 6 ). (3.4 mmol) in anhydrous 1,2-dichloroethane (20 mL) and acetic acid (3.4 mmol). The mixture was allowed to stir at room temperature for 30 minutes, followed by addition of sodium triacetoxyborohydride (8.5 mmol). After stirring at room temperature for 16 hours, the final reaction mixture was washed with aqueous NaOH (5M; 2 x 10 mL) and dichloromethane (2 x 20 mL). The organic extract was dried over MgSO4, filtered, and the solvent evaporated. The crude product was purified by column chromatography (silica gel, ethyl acetate/n-hexane 3/7). 
N-1H-1,2,3,4-Tetraazol-5-yl-dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-

S.1.4. Synthetic route to tetraoxanes
The synthetic approach followed to tetraoxanes is depicted in Schemes S7 to S11. Synthetic Prepared according to general procedure 3 to give LC137 as a white solid (32% yield); m.p.
57-59º C (Lit. 7 55-58º C -1,3'-[1,2,4,5]tetraoxane-6',2''-tricyclo[3.3.1.1 3,7 ]decane]-4-carboxylic acid, LC153. 9
Dispiro[cyclohexane
To a solution of LC138 (4 mmol) in methanol (15 mL) was added a solution of potassium hydroxide (20 mmol) in water (6 mL). The mixture was refluxed for 6 hours. Then the solution was allowed to cool to room temperature and concentrated under reduced pressure.
The crude was taken up in water (50 ml) and washed with dichloromethane (30 ml to give product. 6',2''-tricyclo[3.3.1.1 3,7 ]decane], PA5.
4-[4-(Tert-butoxycarbonylamino)butylamino]dispiro[cyclohexane-1,3'-[1,2,4,5]tetraoxane-
Prepared according to general procedure 4 to give PA5 as yellow oil (32% yield N-1H-1,2,3,4-Tetraazol-5-yl-dispiro[cyclohexane-1,3'-[1,2,4,5]tetraoxane-6',2''tricyclo[3.3.1.1 3,7 ]decan]-4-ylamine, LC163. 6 Prepared according to general procedure 4 to give LC163 as a white solid (95% yield); m.p. 6',2''-tricyclo[3.3.1.1 3,7 ]decane]-4-carboxamide, PA6.
N-[4-(Tert-butoxycarbonylamino)butyl]-dispiro[cyclohexane-1,3'-[1,2,4,5]tetraoxane-
Prepared according to general procedure 5 to give PA6 as a white solid (54% yield). m.p. Butyl-dispiro[cyclohexane-1,3'-[1,2,4,5]tetraoxane-6',2''-tricyclo[3.3.1.1 3,7 ]decane]-4carboxamide, LC167.
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Prepared according to general procedure 5 to give LC167 as light yellow oil. (20% yield [cyclohexane-1,3'-[1,2,4,5]tetraoxane-6',2''-tricyclo[3.3.1.1 3,7 ]decan]-4yl)methoxy}-1H-1λ 6 ,2-benzisothiazole-1,1-dione, LC177. [cyclohexane-1,3'-[1,2,4,5]tetraoxane-6',2''-tricyclo[3.3.1.1 3,7 ]decan]-4yl)methyl} (2-methyl-2H-1,2,3,4-tetraazol-5-yl) [cyclohexane-1,3'-[1,2,4,5]tetraoxane-6',2''-tricyclo[3.3.1.1 3,7 ]decan]-4- (1-methyl-1H-1,2,3,4-tetraazol-5-yl) 
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S.2. Spectra of the compounds
S3.2. In vitro antileishmanial evaluation on intramacrophage amastigotes.
The determination of the cytotoxicity as presented above, was necessary to use the highest drug concentrations to be studied on the intramacrophage amastigote model. Miltefosine was used as the reference drug.
S4. In vivo antileishmanial Screening
S4.1. Animal and housing
The animal phase of these studies was conducted at Animex platform of University Paris-Saclay which is committed to the highest standards of laboratory animal welfare and is subject to legislation under the agreement number C 92-019-01. All procedures involving animals were conducted humanely and were performed by or under the direction of trained and experienced personnel. The protocol was reviewed and approved by the Institutional Ethics Committee for Animal Use from Université Paris-Sud (CEEA 26-063/2013) prior to study initiation. The veterinarian was consulted in the overall study design for this study type.
These studies were conducted under protocol APAFIS 17860-2018112818574072vl. Swiss 
